Champions Oncology, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended April 30, 2021; comparative period ended April 30, 2020. Although the request metadata refers to “2020 Q4,” this filing is an annual report for fiscal 2021, not a quarterly filing. Filed July 26, 2021.
Business context
Champions Oncology provides oncology research services to biopharmaceutical companies, using patient-derived xenograft (PDX) models and computational, pharmacology, and biomarker platforms. Research services are the primary revenue source. The company launched its Lumin Bioinformatics SaaS product in fiscal 2021 and is also developing early-stage therapeutic discovery programs.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $41.040 million | $32.123 million |
| Gross margin | 47.7% | 47.1% |
| Operating income (loss) | $366,000 | $(1.921) million |
| Net income (loss) | $362,000 | $(2.093) million |
| Operating cash flow | $(1.681) million | $2.905 million |
| Investing cash flow | $(3.169) million | $(2.220) million |
| Financing cash flow | $1.195 million | $4.420 million |
- Revenue grew 27.8%, attributed to more and larger studies, expanded platforms and services, and demand for more complex study designs. Pharmacology services contributed $39.473 million; personalized oncology services contributed $166,000; other TOS revenue, including flow cytometry and SaaS, contributed $1.401 million.
- Cost of oncology services was $21.446 million. R&D was $7.196 million, up 22.9%; sales and marketing was $5.520 million, up 30.1%. Management linked higher spending to platform, discovery, and sales-team expansion.
- Cash declined to $4.687 million from $8.342 million. Working capital was $1.4 million and accumulated deficit was $72.5 million. Management said available cash and anticipated improved operating cash flows should fund operations through at least August 2022; additional capital may be needed if that outlook is not met.
- Current liabilities were $11.199 million, including $6.256 million deferred revenue. Operating lease liabilities totaled $9.601 million ($818,000 current and $8.783 million non-current); future minimum operating lease payments were $21.014 million. The filing reports no off-balance-sheet debt or similar obligations.
- Property and equipment purchases were $3.281 million, primarily reflecting additional laboratory equipment and software development. Operating cash flow was negative despite positive net income, principally alongside increases in receivables and prepaid expenses and lower accounts payable.
Material changes, outlook and risks
- The company moved from a net loss to modest net income, while operating cash flow swung from positive to negative. Gross margin increased slightly, from 47.1% to 47.7%.
- Lumin launched in fiscal 2021; $484,000 of initial software costs was placed in service, and $991,000 of additional development costs remained in assets in progress at year-end. SaaS revenue was included in other TOS revenue, but the filing does not provide a separate SaaS revenue figure.
- Laboratory capacity expanded through additional Rockville premises, with new operating lease assets and liabilities recognized. Rent expense increased to $1.247 million from $955,000.
- No specific revenue, earnings, or margin guidance is provided. Management’s stated liquidity outlook extends through at least August 2022 and depends partly on improved operating cash flows.
- Internal controls: Management concluded disclosure controls and internal control over financial reporting were ineffective at April 30, 2021 because of a material weakness in controls over identifying and accounting for royalty obligations. The company said it had begun remediation. Immaterial prior-period errors were corrected: fiscal 2020 cost of services and net loss each increased by $118,000; accrued liabilities increased by $219,000 as of April 30, 2020.
- Key risks include continued losses or cash burn, dependence on research services, competition, customer study cancellations, early-stage drug-development uncertainty, potential changes in regulation of laboratory-developed tests, reliance on specialized employees and facilities, and possible dilution if new capital is raised. The company said COVID-19 had not materially affected operations as of the filing date, but future effects were uncertain.
- The independent auditor issued an unqualified opinion on the financial statements. Its critical audit matter was revenue recognition, involving management estimates of progress toward completion of service contracts.
Most important facts for investors to verify
- Whether growth converts into sustained positive operating cash flow, given the $1.681 million operating cash outflow and $4.687 million year-end cash balance.
- Progress on remediation of the material weakness in royalty accounting controls and whether future filings report effective controls.
- Revenue mix, customer demand, and commercial traction for Lumin, which launched during the year but had no separately stated revenue figure.
- Execution and costs associated with expanded laboratory leases, including the $21.014 million of disclosed future minimum lease payments.
- Whether management’s stated liquidity runway through at least August 2022 is achieved without additional financing or material shareholder dilution.